➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
Baxter
AstraZeneca
McKinsey
Medtronic

Last Updated: September 26, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR NATESTO

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Natesto

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02611154 ↗ Intranasal Delivery of Testosterone and Its Effect on Doping Markers Active, not recruiting Partnership for Clean Competition Phase 4 2015-11-01 Hypothesis: Intranasal administration of exogenous testosterone results in a characteristic profile during anti-doping testing, which is different than the profile seen when testosterone is administered into muscle, on skin or under the tongue. Objective: The investigators aim to characterize the unique steroid doping profile following administration of intranasal testosterone to healthy, active volunteer subjects.
NCT02611154 ↗ Intranasal Delivery of Testosterone and Its Effect on Doping Markers Active, not recruiting Sports Medicine Research and Testing Laboratory Phase 4 2015-11-01 Hypothesis: Intranasal administration of exogenous testosterone results in a characteristic profile during anti-doping testing, which is different than the profile seen when testosterone is administered into muscle, on skin or under the tongue. Objective: The investigators aim to characterize the unique steroid doping profile following administration of intranasal testosterone to healthy, active volunteer subjects.
NCT02611154 ↗ Intranasal Delivery of Testosterone and Its Effect on Doping Markers Active, not recruiting University of Utah Phase 4 2015-11-01 Hypothesis: Intranasal administration of exogenous testosterone results in a characteristic profile during anti-doping testing, which is different than the profile seen when testosterone is administered into muscle, on skin or under the tongue. Objective: The investigators aim to characterize the unique steroid doping profile following administration of intranasal testosterone to healthy, active volunteer subjects.
NCT02937740 ↗ Open-Label Study, Evaluating Patient Satisfaction and Symptom Improvement When Treating Male Hypogonadism With Natestoâ„¢ Recruiting Acerus Pharmaceuticals Corporation Phase 4 2016-10-01 Multicenter study consisting of two study periods as follows: a 90-day Treatment Period, with potential extension by 30 days for those patients requiring a dose increase, as determined by the treating physician. Participants receiving 122.5mg of NATESTO (5.5 mg of testosterone) per nostril twice daily may have an increased daily dose adjustment on Day 90, based on their hypogonadism symptoms.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Natesto

Condition Name

Condition Name for Natesto
Intervention Trials
Hypogonadism, Male 3
Hypogonadism 2
Testosterone Deficiency 1
Steroid Doping 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Natesto
Intervention Trials
Hypogonadism 5
Eunuchism 3
Infertility, Male 1
Infertility 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Natesto

Trials by Country

Trials by Country for Natesto
Location Trials
United States 11
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Natesto
Location Trials
Florida 2
California 1
Arkansas 1
Arizona 1
Alabama 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Natesto

Clinical Trial Phase

Clinical Trial Phase for Natesto
Clinical Trial Phase Trials
Phase 4 5
Early Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Natesto
Clinical Trial Phase Trials
Not yet recruiting 3
Recruiting 2
Active, not recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Natesto

Sponsor Name

Sponsor Name for Natesto
Sponsor Trials
Acerus Pharmaceuticals Corporation 3
University of Miami 2
Sports Medicine Research and Testing Laboratory 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Natesto
Sponsor Trials
Other 6
Industry 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Medtronic
Moodys
Boehringer Ingelheim
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.